share_log

Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'

Benzinga ·  May 23 20:25

On CNBC's "Mad Money Lightning Round," Jim Cramer said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a "terrific spec" and he recommended buying the same.

On May 9, Recursion Pharmaceuticals reported better-than-expected first-quarter financial results.

Corning Incorporated (NYSE:GLW) has "not been able to generate the kind of return that I've wanted," Cramer said. "I would not be a buyer all the way up here."

On May 7, Mizuho analyst John Roberts initiated coverage on Corning with a Neutral rating and announced a price target of $36.

When asked about Intuitive Machines, Inc. (NASDAQ:LUNR), Cramer said, "I'm not there on that."

On May 14, Intuitive Machines reported a first-quarter GAAP loss of $2.70 per share.

The "Mad Money" host said he would hold off Axon Enterprise, Inc. (NASDAQ:AXON) right now.

On May 6, Axon Enterprise posted better-than-expected results for its first quarter, reporting adjusted earnings of $1.15 per share beating market estimates of 94 cents per share.

"I like defense contractors," Cramer said when asked about Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS). "I think you stay on it, maybe even buy more."

On May 7, Kratos Defense & Security posted stronger-than-expected results for its first quarter.

Merit Medical Systems, Inc. (NASDAQ:MMSI) is "good," Cramer said.

On April 30, Merit Medical Systems posted upbeat results for the first quarter.

Price Action:

  • Corning shares gained 0.3% to settle at $36.58 on Wednesday.
  • Axon shares fell 1.1% to close at $284.87 on Wednesday.
  • Recursion Pharmaceuticals shares slipped 1.6% to settle at $9.36.
  • Intuitive Machines shares fell 1.2% to settle at $5.06 on Wednesday.
  • Kratos Defense shares fell 1.3% to settle at $21.41.
  • Merit Medical shares fell 0.2% to close at $82.14 on Wednesday.

Image: Shutterstock

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment